2- cyano- 3- hydroxy- N- (4- (trifluoromethyl)phenyl)- 2- hepten- 6- ynamide

structure in first source; a derivative of A77 1726, the active metabolite of the antirheumatic drug leflunomide, where the isoxazole ring has opened to become a nitrile and an alkyne

Also Known As:

2-cyano-3-hydroxy-N-(4--(trifluoromethyl)phenyl)-2-hepten-6-ynoic acid; FK 778; FK-778; FK778; HMR 1715; HMR-1715; MNA 715; MNA-715; MNA-X 920715; X 920715; X-920715; malononitrilamide 715; malononitrilamide-715

Networked: 23 relevant articles (3 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kloppenburg, Geoffrey: 2 articles (03/2009 - 01/2009)
2.	Stassen, Frank: 2 articles (03/2009 - 01/2009)
3.	de Graaf, Rick: 2 articles (03/2009 - 01/2009)
4.	Deuse, Tobias: 2 articles (01/2007 - 01/2007)
5.	Haddad, Munif: 2 articles (01/2007 - 01/2007)
6.	Pelletier, Marc P: 2 articles (01/2007 - 01/2007)
7.	Reichenspurner, Hermann: 2 articles (01/2007 - 01/2007)
8.	Robbins, Robert C: 2 articles (01/2007 - 01/2007)
9.	Schrepfer, Sonja: 2 articles (01/2007 - 01/2007)
10.	Schäfer, Hansjörg: 2 articles (01/2007 - 01/2007)

Related Diseases

1.	Infections 01/15/2005 - "Mechanistic study of malononitrileamide FK778 in cardiac transplantation and CMV infection in rats." 07/01/2007 - "The association of tacrolimus and FK778 from day 1, compared to the delayed administration of FK778 from day 7, results in a significant reduction of infections and postoperative complications." 01/01/2005 - "Treatment of HCMV-infected cells with FK778 prevented the appearance of HCMV proteins some 12-24h post infection, and inhibited viral DNA synthesis. "
2.	Fibrosis (Cirrhosis) 01/01/2007 - "To investigate the efficacy of the malononitrilamide FK778 to prevent vascular smooth muscle cell (SMC) migration/proliferation, and vascular fibrosis, the key events in restenosis development using in vivo and in vitro studies. " 01/01/2007 - "The malononitrilamide FK778 proved highly efficacious against restenosis development by targeting two major components of intimal hyperplasia: SMC proliferation/migration and vascular fibrosis. "
3.	Neointima 03/01/2009 - "The effect of FK778 treatment on neointima formation in vivo was assessed in an autologous epigastric vein-to femoral artery interposition graft model in rats. " 03/01/2009 - "We examined the inhibitory potential of FK778 on venous SMC proliferation and neointima formation in an experimental venous bypass graft model. " 07/01/2005 - "In both dose groups, there was a trend toward inhibition of neointima formation when the 5-day course of FK778 was started before or 1 day after the intervention. " 03/01/2009 - "In vivo, 3-week oral treatment with FK778 (15 mg/kg/d) significantly reduced neointima formation and stenosis in venous bypass grafts. " 03/01/2009 - "We show that the immunosuppressive agent FK778 can prevent neointima formation in experimental venous bypass grafts by inhibiting venous SMC proliferation. "
4.	Hyperplasia 01/01/2009 - "Also, our results suggest a prospective role for the new immunosuppressive drug FK778 in the prevention of (CMV-mediated) vein graft intimal hyperplasia." 01/01/2009 - "Furthermore, we evaluated the potential of FK778 to prevent intimal hyperplasia. " 01/01/2009 - "FK778 attenuates cytomegalovirus-enhanced vein graft intimal hyperplasia in a rat model." 07/01/2005 - "With the higher dose, suppression of intimal hyperplasia was significant when FK778 was administered between days 1 and 5 after angioplasty (group 2b; P<.01). " 01/01/2007 - "The malononitrilamide FK778 proved highly efficacious against restenosis development by targeting two major components of intimal hyperplasia: SMC proliferation/migration and vascular fibrosis. "
5.	Proteinuria 01/01/2010 - "At week 16, rats with I/R injury and FK778 treatment had lower proteinuria compared with placebo-treated rats (I/R 3 mg: 48.42 +/- 26.16, I/R 10 mg 27.28 +/- 21.86 vs. Placebo: 70.13 +/- 50.19 mg/day, P < 0.05). " 03/27/2007 - "Continuous treatment with FK778 ameliorated the progression of CAN, whereas late treatment reduced proteinuria and resulted in a similar grade of CAN as compared to animals with continuous treatment. " 04/27/2003 - "Recipients treated with FK778 for 10 days exhibited a dose-dependent decrease in proteinuria and plasma creatinine for the entire 90-day period after transplantation when compared with the allograft control. "

Related Drugs and Biologics

1.	Tacrolimus (Prograf)
2.	Leflunomide (Arava)
3.	Immunosuppressive Agents (Immunosuppressants)
4.	X 910279
5.	Sirolimus (Rapamycin)
6.	Cyclosporine (Ciclosporin)
7.	Creatinine
8.	Proteins (Proteins, Gene)
9.	Protein-Tyrosine Kinases (Tyrosine Kinase)
10.	Viral DNA

Related Therapies and Procedures

1.	Oral Administration
2.	Heart Transplantation (Grafting, Heart)
3.	Transplantation
4.	Therapeutics